Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma.

Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma.

Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended...

Full description

Bibliographic Details
Main Authors: Paweł Gunerka, Kamila Gala, Martyna Banach, Jakub Dominowski, Joanna Hucz-Kalitowska, Krzysztof Mulewski, Agnes Hajnal, Endre G Mikus, Damian Smuga, Marcin Zagozda, Krzysztof Dubiel, Jerzy Pieczykolan, Beata M Zygmunt, Maciej Wieczorek
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0236159

Internet

https://doi.org/10.1371/journal.pone.0236159

Similar Items